Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

.

"These data demonstrate the significant benefits that ACZ885 may provide this young population, both in steroid reduction and in extending the period these children can live free from SJIA flares," said David Epstein, Head of the Pharmaceuticals Division of Novartis. "Novartis is committed to helping improve the health of patients with SJIA and other inflammatory diseases, which is why we are delighted to be sharing these results."

ACZ885 is an investigational fully human monoclonal antibody which neutralizes the key inflammatory mediator, interleukin-1 beta (IL-1 beta), which plays an important role in a number of diseases including SJIA[5].

The incidence of SJIA is estimated to be less than 1 in 100,000 children[6]. It is called 'systemic' because the inflammation affects the whole body, as well as most of the joints[4]. The condition is characterized by potentially life-long, recurrent and painful arthritis flares, skin rashes and daily spiking fevers[2],[4].

Novartis is also presenting a number of other studies at ACR, including a second pivotal Phase III trial of ACZ885 in SJIA, which was previously presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, in September.

About the StudyThe Phase III, two-part study had an open-label, single-arm active treatment in Part I followed by a randomized, double-blind, placebo-controlled, event-driven withdrawal design in Part II[1]. A total of 177 patients between the ages of 1 and 19 years with active SJIA were enrolled in the study[1]. In Part I, patients received a subcutaneous (s.c.) dose of ACZ885 (4 mg/kg, up to 300 mg) every 4 weeks. After 8 weeks, patients who met the adapted ACR Pediatric 30 criteria began tapering (reducing) their steroid use until either: a) the dose had been decreased to less than or equal to 0.5 mg/kg[7] while maintaining the adapted ACR Pediatric 30 Criteria (successful tapering of steroids); or b)
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 PRC Clinical, a Silicon-Valley ... several management and executive appointments effective immediately. , Mike ... (CFO) and member of the Board of Directors. Daniel ... and Sue Dowden will assume the position of Senior ... Chief Operations Officer (COO), has been appointed to the ...
(Date:3/26/2015)... and CINCINNATI , ... plc (LSE: SHP, NASDAQ: SHPG ) and ... three-year, broad research collaboration for rare diseases. The goal ... novel therapies to treat rare diseases with high ... capabilities with Cincinnati Children,s research expertise. As a ...
(Date:3/26/2015)... 26, 2015 "In America," the popular news ... States that is hosted by legendary film actor James Earl ... botany in an upcoming segment. , Botany is commonly ... it is actually quite a bit more complicated than that. ... types of living organisms, from the smallest bacteria known to ...
(Date:3/25/2015)... 2015 Agnition announced today that it ... Farmer, airing for the first time at 7:30 a.m. ... Farmer will explore the extremely important role soil microbes ... a patented Microbial Catalystâ„¢ technology that enhances soil and ... segment will air again on April 28. , A ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... ... out of top five ,global pharmaceutical companies. , ... Rochester, NY (PRWEB) December 1, 2009 -- iCardiac Technologies, ... today that a top five pharmaceutical company has selected iCardiac as a preferred vendor ...
... ... veteran of the high-technology industry, has formed nanoEdge™ Technologies, a business development and intellectual ... to invest in promising technologies and act as a nanotechnology incubator. , ... Monterey, CA (PRWEB) December 1, ...
... Mass November 30, 2009 An international ... and ETH Zrich have demonstrated compact, multibeam, and ... the light spectrum (infrared). By contrast, typical lasers ... wavelength. The innovative multibeam lasers have potential use ...
Cached Biology Technology:Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4Scientists demonstrate multibeam, multi-functional lasers 2
(Date:3/11/2015)... March 11, 2015   The Sync Project™ ... to scientifically measure and harness music to improve ... biometrics and objective measurements of physiology, enabling the ... scale in large populations. It is designed for ... clinicians perform rigorous studies and accelerate the discovery ...
(Date:3/10/2015)... 10, 2015   Tute Genomics , pioneer in ... by next-generation sequencing company PrimBio Research Institute ... targeted gene panel interpretation. PrimBio, a certified ... most current technologies to support the work of experts ... offers two types of exome sequencing services: 1) Targeted ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biometrics ... their offering. The market for biometric ... CAGR of around 14% till 2020 ... will be increasing security needs, government projects and ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... PARK, MD, Nov. 25, 2008 -- Researchers in Ohio ... magnetic resonance -- the physical phenomenon that allows MRI ... the human body. Their discovery, a new mathematical ... informative and sharper images. As described in ...
... -- Dieters or those who consume fewer calories during flu ... virus, according to research by Michigan State University nutritional immunology ... November issue of the Journal of Nutrition , Gardner ... to die during the first few days of infection than ...
... The Oklahoma Experimental Program to Stimulate Competitive Research (EPSCoR) ... National Science Foundation (NSF) and the Oklahoma State Regents ... annual support is renewable for the next five years ... new theme area, "Building Oklahoma,s Leadership Role in Cellulosic ...
Cached Biology News:New discovery may enhance MRI scans, lead to portable MRI machines 2Feed a cold, feed a fever: Research shows calorie cut makes it harder to fight flu 2Oklahoma EPSCoR receives $20 million for biofuels research 2
p21 Ras Immunogen: Recombinant C-H-ras p21(val-12). Storage: 4 C...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....
Biology Products: